摘要
目的研究痛麻杞宁方对大鼠坐骨神经损伤(SNI)的改善作用及机制。方法采用夹闭法复制SNI大鼠模型。将模型大鼠随机分为模型对照组,甲钴胺组(甲钴胺6×10^-4g·kg^-1),痛麻杞宁方高剂量组[30g(生药)·kg^-1]、中剂量组[15g(生药)·kg^-1]和低剂量组[7.5g(生药)·kg^-1],另设假手术组,每组10只。连续灌胃给药6周后,检测各组大鼠坐骨神经指数(SFI)和感觉传导速度(SNCV),腹主动脉取血,检测大鼠血液流变性(红细胞压积、血浆黏度、全血黏度高切值、全血黏度中切值和全血黏度低切值),取大鼠坐骨神经组织HE染色,免疫组化法分析大鼠坐骨神经组织中脑源性神经营养因子(BDNF)、神经生长因子(NGF)和血管内皮生长因子(VEGF)水平,Westernblot测定大鼠坐骨神经组织中NGF和VEGF蛋白表达水平。结果痛麻杞宁方能减轻SNI大鼠坐骨神经组织损伤,显著提高SNI大鼠SFI和SNCV(P<0.01),明显降低红细胞压积、血浆黏度、全血黏度高切值和全血黏度低切值(P<0.05),显著上调大鼠坐骨神经组织中的BDNF、NGF和VEGF的表达及NGF、VEGF的蛋白表达水平(P<0.01)。结论痛麻杞宁方对大鼠实验性SNI具有改善性作用,其作用机制可能与改善血液流变性,促进血管新生,保护神经细胞有关。
OBJECTIVE To study the effect and mechanism of Tongma Qining prescription(TQP)on improving sciatic nerve injury(SNI)in rats.METHODS The SNI model rats were replicated by using hemostatic forceps.The model rats were randomly divided into the model group,the mecobalamine group(mecobalamine 6×10^-4 g·kg^-1),the high-dose group(30 g·kg^-1),the medium-dose group(15 g·kg^-1)and the low-dose group(7.5 g·kg^-1),and the sham operation group was set(10 mice per group).After continuous intragastric administration for 6 weeks,sciatic nerve index(SFI),sensory conduction velocity(SNCV)and hemodynamic indexes were detected in each group.HE staining were employed to detect the pathological alterations of sciatic nerve tissues.Then the expression of BDNF,NGF and VEGF in sciatic nerve were detected by IHCP,the protein expression of NGF and VEGF were detected by Western blot.RESULTS Tongma Qining prescription was able to alleviate sciatic nerve tissue injury in SNI rats,significantly improved SFI and SNCV(P<0.01),observably reduced the hematocrit,plasma viscosity and value of whole blood viscosity(high shearing and low sheating)(P<0.05),and markedly upregulated the expression level of BDNF,NGF,VEGF and the protein expression level of NGF,VEGF(P<0.01).CONCLUSION The Tongma Qining prescription can significantly improve SNI in rats.Its action mechanism may be related to improving blood rheology,promoting angiogenesis and protecting nerve cells.
作者
贺克
史文新
张红霞
李彩霞
刘丽华
刘姣
HE Ke;SHI Wen-xin;ZHANG Hong-xia;LI Cai-xia;LIU Li-hua;LIU Jiao(The Fourth Hospital of Shijiazhuang,Shijiazhuang 050000,China;Hebei Medical University,Shijiazhuang 050000,China;Hebei University of Chinese Medicine,Shijiazhuang 050200,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2019年第21期1781-1787,共7页
Chinese Pharmaceutical Journal
基金
河北省科技计划项目资助(1162777194)
